Dongze Li1, Lizhi Zhao2, Jing Yu3, Wei Zhang1, Rongsheng Du3, Xin Liu4, Ying Liu5, You Chen6, Rui Zeng3, Yu Cao1, Zhi Zeng1, Zhiwei Zhao7, Jiang Wu8. 1. Department of Emergency Medicine, West China Hospital, Sichuan University, Chengdu, China. 2. Department of Cardiology, Second Affiliated Hospital of Southwest Medical University, Luzhou, China. 3. Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China. 4. Department of Pharmacology, Harbin Medical University, Harbin, China. 5. Department of Emergency Medicine, First Affiliated Hospital of Southwest Medical University, Luzhou, China. 6. Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. 7. West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, China. Electronic address: zzw2002400@126.com. 8. West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, China. Electronic address: jw@scu.edu.cn.
Abstract
BACKGROUND: Risk associations between lipoprotein-associated phospholipase A2 (Lp-PLA2) and adverse outcomes in patients with coronary heart disease (CHD) remain unclear. The aim of the meta-analysis was to investigate the association between Lp-PLA2 and prognosis of CHD. METHODS: PubMed and Embase were examined for prospective studies published before June 2016. Multivariate-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for the risk of adverse outcomes according to Lp-PLA2 activity or mass were extracted, pooled, and weighted using generic inverse-variance and random-effect modeling. RESULTS: Fifteen studies with 30,857 participants were included. Overall, higher Lp-PLA2 activity or mass was not significantly related to increased risk of long-term all-cause mortality. However, higher Lp-PLA2 activity or mass was independently associated with an increased risk of long-term cardiovascular events, with pooled HR for cardiovascular events of 1.55 (95% CI, 1.08-2.23; P=0.018) and 1.62 (95% CI, 1.09-2.41; P=0.017), respectively. The prognostic value of Lp-PLA2 in predicting cardiovascular events was observed in patients with stable CHD who were not receiving therapies for inhibiting Lp-PLA2. CONCLUSIONS: Greater Lp-PLA2 activity or mass was independently associated with cardiovascular events in patients with CHD, particularly in patients with stable CHD who were not receiving therapies for inhibiting Lp-PLA2.
BACKGROUND: Risk associations between lipoprotein-associated phospholipase A2 (Lp-PLA2) and adverse outcomes in patients with coronary heart disease (CHD) remain unclear. The aim of the meta-analysis was to investigate the association between Lp-PLA2 and prognosis of CHD. METHODS: PubMed and Embase were examined for prospective studies published before June 2016. Multivariate-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for the risk of adverse outcomes according to Lp-PLA2 activity or mass were extracted, pooled, and weighted using generic inverse-variance and random-effect modeling. RESULTS: Fifteen studies with 30,857 participants were included. Overall, higher Lp-PLA2 activity or mass was not significantly related to increased risk of long-term all-cause mortality. However, higher Lp-PLA2 activity or mass was independently associated with an increased risk of long-term cardiovascular events, with pooled HR for cardiovascular events of 1.55 (95% CI, 1.08-2.23; P=0.018) and 1.62 (95% CI, 1.09-2.41; P=0.017), respectively. The prognostic value of Lp-PLA2 in predicting cardiovascular events was observed in patients with stable CHD who were not receiving therapies for inhibiting Lp-PLA2. CONCLUSIONS: Greater Lp-PLA2 activity or mass was independently associated with cardiovascular events in patients with CHD, particularly in patients with stable CHD who were not receiving therapies for inhibiting Lp-PLA2.
Authors: Andreana De Mauri; Deborah Carrera; Marco Bagnati; Roberta Rolla; Matteo Vidali; Doriana Chiarinotti; Marco Pane; Angela Amoruso; Mario Del Piano Journal: Nutrients Date: 2022-04-14 Impact factor: 6.706